Advances in bone tissue engineering and three-dimensional printing: Current strategies and future perspectives in orthopaedics

Abstract

Bone defects resulting from trauma, infection, tumor resection, or congenital malformations remain prevalent and challenging in orthopedic practice, particularly in the repair of large segmental defects and complex anatomical sites where conventional surgical approaches have limitations. Recent advances in tissue engineering combined with three-dimensional (3D) printing technology have introduced novel strategies for personalized and precise bone regeneration. By integrating biocompatible scaffolds, osteogenic cells, and bioactive factors, and leveraging 3D printing to fabricate scaffolds that conform to patient-specific anatomical and functional requirements, this approach is progressively transitioning from experimental research to clinical application. This review summarizes recent progress in this field, focusing on commonly used materials, printing techniques, and clinical applications in craniofacial, spinal, and long bone reconstruction. With ongoing technological refinement and multidisciplinary collaboration, the integration of tissue engineering and 3D printing is poised to play an increasingly pivotal role in orthopedic practice, ushering in a new era of individualized and precise bone defect repair.

Key Words: Bone tissue engineering; Scaffold materials; Stem cells; Bone regeneration; Bioprinting; Orthopaedic applications; Clinical translation

Core Tip: The combination of bone tissue engineering and three-dimensional printing presents a powerful strategy for tailored repair of bone defects. By integrating biocompatible scaffolds, stem cells, and bioactive molecules with precise three-dimensional fabrication, it is possible to create constructs that closely replicate native bone structure and support effective regeneration. Recent advances in smart biomaterials and bioprinting techniques have further improved scaffold functionality and therapeutic outcomes. However, challenges, including vascularization, controlled scaffold degradation, and clinical translation, remain to be fully addressed. Ongoing interdisciplinary efforts will be crucial in overcoming these hurdles and advancing these promising technologies into routine orthopaedic care.

INTRODUCTION

Large segmental bone defects resulting from trauma, tumor resection, infection, or congenital malformations continue to pose major challenges in orthopaedic surgery. Although autografts and allografts remain widely used in clinical practice, their application is limited by donor site morbidity, immunogenic responses, and transmission of infections[1]. Bone tissue engineering has emerged as a compelling strategy for overcoming these limitations by combining biomaterials, cells, and signaling molecules to promote bone regeneration[2]. Among recent technological innovations, three-dimensional (3D) printing has significantly advanced the precision and functionality of scaffold fabrication. This technique enables the production of scaffolds with tailored architectures, controlled porosity, and site-specific mechanical properties, thereby meeting both structural and biological demands[3,4].

Techniques such as electrospinning, stereolithography (SLA), selective laser melting (SLM), and fused deposition modeling (FDM) have been applied to fabricate scaffolds from a wide range of biodegradable materials, including polycaprolactone (PCL), polylactic acid (PLA), hydroxyapatite (HA), and graphene-based composites[5]. A particularly promising development is the rise of smart scaffolds, which are engineered not only for mechanical support but also to interact dynamically with the biological microenvironment.

These scaffolds can respond to internal or external stimuli - such as temperature or enzymatic activity - by releasing therapeutic agents or modulating cellular behavior, thereby enhancing the regenerative process[6,7]. Advancements in 3D bioprinting have further pushed the boundaries of tissue engineering by enabling the precise placement of cells, growth factors, and biomaterials within bioactive scaffolds (Figure 1). This approach holds great potential for creating patient-specific implants capable of supporting in situ bone formation[8,9]. Recent studies have demonstrated that materials like graphene and black phosphorus nanosheets not only support stem cell proliferation but also significantly accelerate osteogenic differentiation, positioning them as valuable components of next-generation scaffolds[10]. Some of these technologies have already entered the clinical landscape - products such as Osteoplug^® exemplify how bioresorbable scaffolds fabricated by 3D printing are being translated into real-world orthopaedic applications[11]. In this review, we highlight recent advances in bone tissue engineering and 3D printing for orthopedics, focusing on material innovation, scaffold fabrication, biological functionality, and clinical translation, while also providing a critical discussion of the current and future challenges in the field.

Figure 1 Conceptual illustration of bioactive scaffold-mediated repair of critical-sized bone defects. A critical-sized cranial bone defect represents a clinically significant loss of bone structure that cannot heal spontaneously. To address this, a three-dimensional-printed bioactive scaffold (middle) is designed to fill the defect and serves as a temporary structural framework. The scaffold can be seeded with stem cells and loaded with osteogenic and angiogenic factors, such as bone morphogenetic proteins and growth factors, which are gradually released into the defect site. These components synergistically promote cell recruitment, vascularization, and new bone formation. Ultimately, the combined effect of mechanical support and osteoinductive cues facilitates the regeneration of functional bone tissue, restoring both structure and biomechanical integrity. VEGF: Vascular endothelial growth factor; FGF-2: Fibroblast growth factor-2; 3D: Three-dimensional.

CURRENT STRATEGIES IN BONE TISSUE ENGINEERING

Scaffold materials for bone regeneration

Scaffolds play a central role in bone tissue engineering, offering a 3D matrix that supports cell adhesion, proliferation, migration, and extracellular matrix deposition. For successful bone regeneration, ideal scaffolds must closely mimic the structural and mechanical properties of native bone while being biocompatible, osteoconductive, and capable of synchronizing degradation with new tissue formation. Among the most widely used materials are HA and β-tricalcium phosphate, while emerging candidates such as black phosphorus nanosheets and bioactive glasses have shown promising osteoinductive potential in recent preclinical studies[12,13].

However, the inherent brittleness of these materials limits their use in load-bearing applications, prompting researchers to explore more adaptable alternatives. Incorporating HA at the nanoscale has emerged as an effective strategy, as nano-HA offers a larger surface area and superior cellular interactions, enhancing osteogenic activity and integration with host bone[14]. Moreover, HA-collagen composites provide a more biomimetic microenvironment that mirrors the natural bone structure and promotes favorable biological responses[15]. In addition to ceramics, polymers - both natural and synthetic - have become essential components in scaffold design. Natural polymers such as collagen, gelatin, chitosan, and bacterial cellulose offer excellent biocompatibility and cellular affinity[16]. Synthetic polymers like PLA, PCL, and poly(lactic-co-glycolic acid) (PLGA) provide more predictable degradation profiles and mechanical behavior[17].

Despite substantial progress in the design and optimization of scaffold materials, several challenges remain before their full clinical translation can be realized. Most current studies focus on enhancing osteogenic or mechanical properties in isolation, often overlooking the dynamic interplay between biodegradation, vascularization, and immune modulation within the defect microenvironment. Moreover, discrepancies between preclinical performance and in vivo outcomes highlight the need for more physiologically relevant evaluation models that mimic human bone healing processes. Future scaffold development should therefore move beyond the mere combination of bioactive and structural components, aiming instead for intelligent, adaptive systems capable of responding to local biological cues and orchestrating the sequential phases of bone regeneration. Only through such integrative and multidisciplinary approaches can scaffold-based strategies achieve consistent, predictable, and long-term success in clinical bone repair.

Bioactive molecules and growth factors

Bioactive molecules play a pivotal role in bone tissue engineering by orchestrating the complex biological processes such as migration, proliferation, differentiation, and matrix synthesis - key steps in osteogenesis and angiogenesis. Among them, bone morphogenetic proteins (BMPs), vascular endothelial growth factor (VEGF), and transforming growth factor-beta have been extensively studied and applied in both experimental and clinical contexts[18,19]. BMP-2 and BMP-7, for instance, are known to induce the osteogenic differentiation of mesenchymal stem cells (MSCs), while VEGF enhances neovascularization within scaffolds, promoting nutrient transport and integration with host tissues[20,21]. Transforming growth factor-beta contributes to early bone formation and extracellular matrix production, although its activity must be tightly regulated to avoid fibrosis or excessive tissue remodeling[22,23].

Despite their proven biological effects, the clinical translation of growth factors faces several obstacles. Chief among them is the challenge of delivering these proteins in a controlled, localized, and sustained manner. Systemic administration is inefficient and often associated with off-target effects and rapid degradation. To address this, a wide range of delivery systems has been developed to encapsulate growth factors and release them gradually at the target site. Microspheres composed of biodegradable polymers such as PLGA, for example, can be embedded within scaffolds to provide sustained release over days or weeks[24].

Hydrogels, due to their high-water content and tissue-mimicking properties, have also emerged as effective carriers. Coating scaffolds with growth factor-laden hydrogels enables uniform distribution and enhances the local microenvironment by maintaining therapeutic concentrations where needed most[25]. Recent innovations in scaffold design have introduced stimuli-responsive systems capable of releasing bioactive agents in response to specific environmental cues. These smart scaffolds, inspired by physiological processes, can adjust their behavior according to pH changes, temperature shifts, mechanical stress, or magnetic fields[26]. For example, thermosensitive hydrogels can swell or collapse at body temperature to trigger the release of encapsulated proteins[27]. Similarly, magnetic nanoparticles embedded within scaffolds can be remotely activated to release growth factors in a controlled manner, offering a minimally invasive approach to modulate tissue regeneration[28]. Such systems provide precise spatiotemporal control over the release profile, an advantage particularly useful in complex or chronic bone defects requiring stage-specific therapeutic inputs. However, optimizing the ratios, timing, and release kinetics of such combinations remains challenging. Overlapping or antagonistic signaling pathways can reduce efficacy or trigger undesired effects, emphasizing the need for refined delivery strategies and deeper mechanistic understanding. Layered scaffolds or compartmentalized designs, which allow separate loading and independent release of different factors, represent promising solutions under investigation. Gene-activated scaffolds, for instance, enable cells to locally produce growth factors by delivering plasmids or viral vectors encoding osteogenic genes[29]. This approach bypasses the need for exogenous protein administration and allows sustained, cell-mediated factor release. Exosome-based delivery systems are also under exploration due to their inherent stability, biocompatibility, and capacity to carry complex cargo, including proteins and microRNAs involved in bone regeneration[30].

In summary, growth factor-based strategies remain fundamental to bone tissue engineering, yet their translation is limited by uncontrolled release, rapid degradation, and signaling complexity. Advances in biomaterial design - such as PLGA microspheres, hydrogel coatings, and stimuli-responsive or compartmentalized scaffolds - have improved local delivery and temporal control but still face challenges in synchronizing multiple cues within dynamic tissue environments. Gene-activated and exosome-based systems represent an emerging shift toward cell-instructive, self-regulated therapies, enabling sustained in situ factor production or cargo transfer. However, variability in gene expression, exosome heterogeneity, and manufacturing reproducibility continue to impede clinical translation. Overall, future progress requires a mechanistic understanding of multi-factor interactions and the development of standardized, scalable platforms to ensure safe and effective regenerative outcomes.

Cell sources for bone tissue engineering

Cells serve as the biological driving force in bone tissue engineering, orchestrating the processes of osteogenesis, angiogenesis, and immune modulation. Among the various cell types explored, MSCs remain the cornerstone due to their multilineage differentiation potential, ease of isolation, and relative immunoprivilege[31]. Bone marrow-derived MSCs are the most studied, demonstrating robust osteogenic potential and clinical relevance[32]. However, their harvest is invasive and yields limited cell numbers. Adipose-derived MSCs, in contrast, are more accessible and abundant, though their osteogenic capacity may be slightly inferior[33]. Umbilical cord-derived MSCs have emerged as a non-invasive and ethically acceptable source with high proliferative capacity and reduced immunogenicity, making them highly attractive for allogeneic applications[34]. In recent years, induced pluripotent stem cells (iPSCs) have garnered attention as a theoretically unlimited and patient-specific cell source. iPSCs can be reprogrammed from somatic cells and subsequently directed toward an osteogenic lineage, offering a personalized approach to bone regeneration[35].

Despite remarkable progress in stem cell-based bone tissue engineering, no single cell type fully meets the criteria of accessibility, scalability, safety, and osteogenic efficacy. MSCs remain the most widely applied due to their multipotency and immunomodulatory properties; however, their performance varies significantly by tissue origin. Bone marrow-derived MSCs exhibit strong osteogenic capacity but are limited by invasive procurement and donor variability. Adipose-derived MSCs provide an abundant and easily harvested alternative, yet often show reduced osteoinductive potential compared to bone marrow-derived MSCs. Umbilical cord-derived MSCs offer an ethically favorable and non-invasive source with high proliferative and immunosuppressive capacities, but their long-term stability and osteogenic maturation require further validation in vivo. iPSCs present an appealing, patient-specific option with theoretically limitless expansion, though reprogramming efficiency, genomic instability, and potential tumorigenicity remain unresolved barriers.

Collectively, these observations highlight a persistent trade-off between biological potency and clinical practicality, emphasizing the urgent need for standardized manufacturing, long-term safety evaluation, and strategies to integrate multiple cell types synergistically within engineered bone constructs.

ADVANCES IN 3D PRINTING TECHNOLOGIES FOR BONE TISSUE ENGINEERING

The integration of 3D printing into bone tissue engineering has transformed scaffold fabrication by enabling anatomically precise, reproducible, and patient-specific architectures. FDM remains one of the most accessible techniques, allowing thermoplastic polymers such as PLA and PCL to be fabricated into macro-porous structures with stable mechanical performance[36]. SLA offers superior spatial resolution through photopolymerization, supporting the creation of intricate geometries and vascular-mimicking channels that are difficult to achieve with extrusion-based systems[37]. Meanwhile, SLM enables the fabrication of metallic and ceramic scaffolds with excellent load-bearing capacity, making it well-suited for applications requiring long-term mechanical stability[38]. Complementary to these, electrospinning provides nanofibrous extracellular matrix-like environments that enhance cell adhesion and early osteogenic signaling, and can be integrated with 3D-printed frameworks to combine micro-scale biological functionality with macro-scale structural support[39].

While these methods collectively expand the design space for bone scaffolds, selecting an optimal printing strategy requires balancing resolution, material compatibility, mechanical requirements, and clinical feasibility. FDM is generally preferred in scenarios prioritizing affordability, rapid prototyping, and patient-specific geometry - such as large but low-complexity constructs - though its limited resolution restricts its use where fine vascular or trabecular features are critical. SLA becomes advantageous when micro-architectures, perfusable channels, or soft-tissue interfaces are required, yet its use is constrained by the narrow range of biocompatible photopolymers and the need for extensive post-curing. For high load-bearing regions such as long bones or spinal implants, SLM offers clear advantages due to its ability to fabricate porous titanium (Ti) or ceramic constructs with mechanical properties approaching native bone; however, the high energy cost, equipment demands, and potential thermal distortion limit its routine clinical adoption. Electrospinning alone is most suitable for applications where biomimicry and early cell signaling are essential - such as interfacial layers or coatings - but its poor thickness control and weak mechanical stability make it insufficient as a standalone scaffold in defect reconstruction.

Consequently, hybrid fabrication strategies are emerging as a rational approach to integrate the strengths of each technology. For example, electrospun nanofibers can be applied to 3D-printed Ti or polymer frameworks to enhance cellular bioactivity, while SLA-defined micro-channels can be incorporated into SLM-based load-bearing implants to improve vascularization. These combinations offer a pathway toward scaffolds that simultaneously meet architectural precision, mechanical robustness, and biological performance requirements. However, technical barriers - including multi-material compatibility, process reproducibility, and cost-effectiveness - remain key obstacles to achieving scalable clinical translation. This decision-oriented framework underscores that no single 3D printing modality is universally optimal; instead, the clinical indication - whether high-load reconstruction, microvascular regeneration, or aesthetic contouring - should dictate the selection or combination of technologies.

CLINICAL APPLICATIONS AND TRANSLATIONAL PROGRESS

Although many 3D-printed scaffolds are still at the preclinical stage, several technologies have now advanced into clinical application, demonstrating meaningful translational potential in orthopedics and craniofacial reconstruction (Table 1). A consistent theme across current evidence is that patient-specific design, controlled porosity, and material-dependent mechanical behavior collectively determine clinical performance. Among available options, customized Ti implants represent the most mature application, particularly for large structural defects where high load-bearing capacity and reliable osseointegration are required.

Table 1 Summary of representative clinical applications of three-dimensional-printed implants.

Ref.	Material	Clinical indication	n	Key outcomes	Follow-up times
Wang et al[40]	Ti	Lumbar fusion	91	Greater restoration of intervertebral height and higher fusion rate vs polyetheretherketone; no increase in complications	> 6 months
Donaldson et al[41]	Ti	Lumbar fusion	50	Subsidence 303%; reoperation 1 case; no infection or device failure	11.3 months (range 7-24)
Broekhuis et al[42]	Ti	Pelvic reconstruction	15	Stable fixation, satisfactory limb function; implant survival 733%	33.8 months (IQR: 24.0-78.1)
Boyle et al[43]	Ti	Pelvic reconstruction	106	Implant retention 96% (95%CI: 90-99); infection-free survival 85%-86%; intra-op complications 4.1%	4.1 years (range 6-10)
Yoon et al[44]	Ti	Cranioplasty	40	Excellent volumetric symmetry (DSC = 0.75); 75% “very satisfactory” cosmetic outcome; no reoperation	6 months
Ebel et al[45]	Poly(methyl methacrylate)	Cranioplasty	31	Cosmetic results comparable to industrial implants; minor wound irritation; reduced cost	33.3 months (range 127-53.9)
Toh et al[11]	PCL	Chronic subdural hematoma	126	High satisfaction; no increase in recurrence or infection	24 months (IQR: 15-37)
Li et al[46]	Ti	Mandibular reconstruction	5	Stable occlusion, excellent facial symmetry (< 4.5 mm deviation); no flap necrosis	15.8 months (range 12-19)

IQR: Interquartile range; CI: Confidence interval; DSC: Differential scanning calorimetry; PCL: Polycaprolactone.

In spinal surgery, findings from Wang et al[40] and Donaldson et al[41] collectively indicate a clear performance trend: Porous Ti cages demonstrate more favorable fusion, better intervertebral height restoration, and lower overall subsidence rates compared with conventional polyetheretherketone implants. While individual studies report different complication profiles, subsidence remains generally low (approximately 3%), and device-related failures are rare. When viewed together, these data suggest that porous lattice architecture - rather than the implant’s material alone - contributes to stable load transfer and early osseointegration, providing a biomechanical rationale for the improved outcomes consistently reported across studies.

A similar pattern emerges in pelvic reconstruction. Despite anatomical complexity and high biomechanical demands, both Broekhuis et al[42] and Boyle et al[43] document durable fixation and high implant retention rates using patient-specific 3D-printed Ti constructs. Infection remains the most frequent complication across studies, particularly in oncologic cases involving extensive soft-tissue dissection; however, the mechanical survival of the implants remains high (73%-96%), and revision rates attributable to implant failure are comparatively low. When synthesized, these findings suggest that 3D-printed Ti implants provide predictable mechanical stability in the pelvis, but clinical success also depends heavily on soft-tissue management, host biology, and infection control - factors that must be integrated into surgical decision-making.

In neurosurgical practice, the literature highlights a broader material spectrum - Ti, poly(methyl methacrylate), and bioresorbable PCL - each fulfilling different clinical priorities. Yoon et al[44] showed that Ti patient-specific implants optimize contour accuracy and long-term cosmetic symmetry, whereas Ebel et al[45] demonstrated that in-house printed poly(methyl methacrylate) provides a cost-efficient alternative with comparable aesthetic results. Meanwhile, the Osteoplug™-C PCL device performs well in burr-hole reconstruction with low recurrence and infection rates[11], confirming that material selection should align with cosmetic demands, defect size, infection risk, and cost considerations, rather than applying a single material across all cranial indications.

In the cranio-maxillofacial domain, the report by Li et al[46] illustrates the highest level of digital integration - combining virtual planning, surgical guides, customized Ti mesh, vascularized bone transfer, and simultaneous dental implantation. Synthesizing across related studies, the key clinical advantage appears not only in reconstruction accuracy but in workflow efficiency: 3D planning and intraoperative guides reduce surgical time, increase predictability, and facilitate single-stage restoration of both anatomy and function. These cases collectively emphasize that the strength of 3D printing lies in procedure orchestration, enabling reconstruction strategies that were previously difficult or impossible to perform.

Overall, current clinical evidence signals a shift from simple structural replacement toward individualized regenerative reconstruction. Across spinal, pelvic, cranial, and maxillofacial applications, several themes consistently emerge: (1) 3D-printed Ti implants offer excellent mechanical reliability but require careful infection management in complex oncologic cases; (2) Material selection must balance load-bearing requirements, aesthetic priorities, and cost constraints; and (3) Treatment success increasingly depends on digital integration rather than the implant alone. Future work should prioritize multicenter trials, standardized outcome measures, long-term survivorship analyses, and systematic cost evaluations. Advances such as bioactive coatings, drug-eluting interfaces, and hybrid degradable-metallic constructs may further strengthen the union between mechanical performance and biological function, accelerating progress toward predictable, patient-specific reconstructive solutions.

CHALLENGES AND FUTURE DIRECTIONS

Despite the rapid evolution of 3D printing and bioprinting technologies for bone tissue engineering, several critical limitations continue to hinder their widespread clinical translation. One of the foremost challenges is the insufficient vascularization within large, implanted scaffolds. Without an adequate blood supply, nutrient diffusion becomes limited, leading to poor cell survival, impaired osteogenesis, and delayed integration with the host tissue[47]. This issue is particularly pronounced in critical-sized defects and load-bearing bones where metabolic demands are high. To address this, various strategies are under investigation, including the co-printing of pre-vascularized networks within scaffolds, as well as the incorporation of angiogenic growth factors such as VEGF[48]. While these approaches have shown encouraging results in preclinical models, translating them into clinically viable, scalable solutions remains a complex task. Another major barrier lies in the mechanical mismatch between the scaffold and the native bone. In load-bearing regions, inadequate mechanical strength or inappropriate stiffness can lead to implant failure, stress shielding, or compromised bone remodeling[49,50]. Composite and hybrid scaffolds, which combine bioresorbable polymers with ceramics or metals, offer a promising route to balance bioactivity with mechanical performance[51]. However, ensuring long-term structural stability and synchronizing scaffold degradation with the rate of new bone formation is a persistent challenge. Premature degradation can result in loss of mechanical support, whereas excessively slow degradation may interfere with normal bone remodeling and integration. Standardization in materials, bioink formulations, and printing parameters is another area requiring urgent attention. Currently, there is considerable variability in the selection of biomaterials, the composition of cell-laden bioinks, and the optimization of printing protocols, which affects reproducibility across studies[52]. This lack of uniformity complicates regulatory approval processes and limits the comparability of clinical outcomes across different research centers. Establishing consensus guidelines on material characterization, mechanical testing, and in vitro/in vivo evaluation would be an important step toward enhancing reproducibility and facilitating translational progress. Finally, scalability and compliance with clinical manufacturing standards remain major obstacles to the routine clinical adoption of 3D bioprinting for bone implants. Although small-scale laboratory studies have proven the feasibility of fabricating complex, patient-specific constructs, most existing systems are not designed for high-throughput production or cost-efficient manufacturing under stringent regulatory requirements. A critical limitation is the scarcity and high cost of 3D bioprinters that can operate under sterile, good manufacturing practice-compliant conditions, which are essential to prevent contamination and ensure consistent quality[53]. Furthermore, the lack of standardized operating protocols, trained personnel, and clear regulatory guidelines hinders the seamless transfer of bioprinting technologies from research to clinical practice. Without robust quality control measures, validated cleaning procedures, and harmonized regulatory frameworks, large-scale clinical implementation remains challenging despite the technology’s demonstrated potential. Addressing these limitations will require not only technical innovation but also the integration of advanced manufacturing pipelines and regulatory frameworks that can support the transition from bench to bedside.

In summary, overcoming the limitations of vascularization, mechanical compatibility, standardization, and scalability is critical for the future success of 3D printed bone scaffolds in clinical practice. Targeted interdisciplinary efforts involving bioengineers, material scientists, and clinicians will be essential to bridge these gaps and fully unlock the regenerative potential of this technology.

CONCLUSION

The integration of bone tissue engineering and 3D printing has transformed the landscape of bone defect repair, offering unprecedented opportunities for patient-specific, biologically functional reconstructions. By combining advanced biomaterials, stem cells, and bioactive molecules with precision fabrication, it is now possible to create scaffolds that closely replicate the structural and mechanical properties of native bone while supporting vascularization and osteogenesis. Developments such as smart and stimuli-responsive scaffolds, endochondral ossification-based strategies, and 3D bioprinting with cell-laden constructs have further expanded the scope of applications, bridging the gap between experimental innovation and clinical feasibility.

Clinical adoption has begun in areas such as craniofacial, spinal, and pelvic reconstructions, with patient-specific implants demonstrating favorable functional outcomes and integration. Nevertheless, challenges remain, particularly in achieving robust vascularization in large constructs, synchronizing scaffold degradation with new tissue formation, and scaling production to meet clinical demand under good manufacturing practice standards. Regulatory uncertainties, cost constraints, and the need for standardized protocols continue to slow widespread translation.

Looking forward, the convergence of 3D printing with microfluidics, bioreactor-based maturation, artificial intelligence-assisted design, and real-time monitoring is expected to accelerate progress. Multi-cellular, hierarchically structured scaffolds capable of dynamic adaptation to the host environment may set the standard for next-generation bone regeneration. By fostering interdisciplinary collaboration among materials scientists, bioengineers, and clinicians, these advances have the potential to make truly personalized, functional, and durable bone repair a routine reality in orthopaedic practice.